Comparing SG&A Expenses: Bio-Techne Corporation vs Amneal Pharmaceuticals, Inc. Trends and Insights

SG&A Expenses: Bio-Techne vs Amneal - A Decade of Growth

__timestampAmneal Pharmaceuticals, Inc.Bio-Techne Corporation
Wednesday, January 1, 20148461500060716000
Thursday, January 1, 2015109679000119401000
Friday, January 1, 2016118757000140879000
Sunday, January 1, 2017109046000199243000
Monday, January 1, 2018230435000240636000
Tuesday, January 1, 2019289598000264359000
Wednesday, January 1, 2020326727000260583000
Friday, January 1, 2021365504000324951000
Saturday, January 1, 2022399700000372766000
Sunday, January 1, 2023429675000378378000
Monday, January 1, 2024396826000
Loading chart...

Unleashing insights

SG&A Expenses: A Tale of Two Companies

In the competitive landscape of the pharmaceutical and biotechnology sectors, understanding the financial dynamics is crucial. Over the past decade, Bio-Techne Corporation and Amneal Pharmaceuticals, Inc. have shown distinct trends in their Selling, General, and Administrative (SG&A) expenses.

From 2014 to 2023, Amneal Pharmaceuticals saw a staggering 408% increase in SG&A expenses, peaking in 2023. This growth reflects their aggressive expansion and market penetration strategies. In contrast, Bio-Techne Corporation's SG&A expenses grew by approximately 523% over the same period, indicating a robust investment in operational efficiency and market presence.

Interestingly, while Amneal's expenses consistently rose, Bio-Techne experienced a slight dip in 2020, only to rebound strongly in subsequent years. This divergence highlights the different strategic approaches these companies have taken in navigating the ever-evolving healthcare landscape.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025